Vitamin D3 triggers antitumor activity through targeting hedgehog signaling in human renal cell carcinoma

Dormoy, Valérian; Beraud, C; Lindner, Véronique; Coquard, Catherine; Barthelmebs, Mariette; Brasse, David; Jacqmin, Didier; Lang, Hervé; Massfelder, Thierry

doi:10.1093/carcin/bgs255

Cited by 41 publications

(32 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…15 They recently reported the potential value of targeting the HH pathway with a Smo inhibitor. 19 Treatment with the HH inhibitor cyclopamine induced apoptosis and inhibited cell proliferation in vitro and in vivo. The specificity of HH inhibition was demonstrated by decreased expression of the downstream proteins Smo and Gli1 as well as the ligand SHH.…”

Section: Discussionmentioning

confidence: 99%

DHH is an Independent Prognosticator of Oncologic Outcome of Clear Cell Renal Cell Carcinoma

et al. 2014

View full text Add to dashboard Cite

To our knowledge we report for the first time that a biomarker of the HH pathway is associated with adverse pathological features and poor disease outcomes in patients with clear cell renal cell carcinoma. DHH may serve as an independent predictor of cancer specific survival in clear cell renal cell carcinoma cases. This supports further evaluation of HH signaling to validate the pathway as a target for novel therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

DHH is an Independent Prognosticator of Oncologic Outcome of Clear Cell Renal Cell Carcinoma

et al. 2014

View full text Add to dashboard Cite

show abstract

“…[163] Vitamin D analogs might also be exerting anti-retinoblastoma tumor effects via targeting of the hedgehog signaling pathway, as has been described for other cancers. [164–165] …”

Section: Pre-clinical Progress In Retinoblastoma Therapeuticsmentioning

confidence: 99%

Progress in Small Molecule Therapeutics for the Treatment of Retinoblastoma

Pritchard¹,

Dyer

Guy

2016

MRMC

View full text Add to dashboard Cite

While mortality is low for intraocular retinoblastoma patients in the developed world who receive aggressive multimodal therapy, partial or full loss of vision occurs in approximately 50% of patients with advanced bilateral retinoblastoma. Therapies that preserve vision and reduce late effects are needed. Because clinical trials for retinoblastoma are difficult due to the young age of the patient population and relative rarity of the disease, robust preclinical testing of new therapies is critical. The last decade has seen advances towards identifying new therapies including the development of animal models of retinoblastoma for preclinical testing, progress in local drug delivery to reach intraocular targets, and improved understanding of the underlying biological mechanisms that give rise to retinoblastoma. This review discusses advances in these areas, with a focus on discovery and development of small molecules for the treatment of retinoblastoma, including novel targeted therapeutics such as inhibitors of the MDMX-p53 interaction (nutlin-3a), histone deacetylase (HDAC) inhibitors, and spleen tyrosine kinase (SYK) inhibitors.

show abstract

“…Mice xenografted with renal cell carcinoma cells yet treated with vitamin D exhibit the absence of tumor development or substantial growth inhibition, suggesting the vitamin D 3 can be used prophylactically to prevent tumor development or regression [88]. …”

Section: Vitamin D and Cancermentioning

confidence: 99%

Molecular Link between Vitamin D and Cancer Prevention

2013

View full text Add to dashboard Cite

The metabolite of vitamin D, 1α,25-dihydroxyvitamin D3 (also known as calcitriol), is a biologically active molecule required to maintain the physiological functions of several target tissues in the human body from conception to adulthood. Its molecular mode of action ranges from immediate nongenomic responses to longer term mechanisms that exert persistent genomic effects. The genomic mechanisms of vitamin D action rely on cross talk between 1α,25-dihydroxyvitamin D3 signaling pathways and that of other growth factors or hormones that collectively regulate cell proliferation, differentiation and cell survival. In vitro and in vivo studies demonstrate a role for vitamin D (calcitriol) in modulating cellular growth and development. Vitamin D (calcitriol) acts as an antiproliferative agent in many tissues and significantly slows malignant cellular growth. Moreover, epidemiological studies have suggested that ultraviolet-B exposure can help reduce cancer risk and prevalence, indicating a potential role for vitamin D as a feasible agent to prevent cancer incidence and recurrence. With the preventive potential of this biologically active agent, we suggest that countries where cancer is on the rise—yet where sunlight and, hence, vitamin D may be easily acquired—adopt awareness, education and implementation strategies to increase supplementation with vitamin D in all age groups as a preventive measure to reduce cancer risk and prevalence.

show abstract

Vitamin D3 triggers antitumor activity through targeting hedgehog signaling in human renal cell carcinoma

Cited by 41 publications

References 46 publications

DHH is an Independent Prognosticator of Oncologic Outcome of Clear Cell Renal Cell Carcinoma

DHH is an Independent Prognosticator of Oncologic Outcome of Clear Cell Renal Cell Carcinoma

Progress in Small Molecule Therapeutics for the Treatment of Retinoblastoma

Molecular Link between Vitamin D and Cancer Prevention

Contact Info

Product

Resources

About